Vitamin D status influences how much calcium is absorbed from the gut, how much parathyroid hormone (PTH) the body releases, and how bones are remodeled. In CKD, the kidneys lose the ability to activate vitamin D, leading to reduced intestinal calcium absorption and often low serum calcium. That drop stimulates PTH production, driving secondary hyperparathyroidism and increased bone turnover, which contributes to renal osteodystrophy. Maintaining adequate vitamin D (or giving active forms when needed) helps suppress PTH synthesis, supports proper bone mineralization, and helps balance calcium and phosphate levels. Because of these intertwined effects on PTH, bone turnover, and mineral balance, vitamin D status is central to managing CKD-MBD.

In CKD-MBD, the vascular system calcifies mainly because phosphate builds up outside the bones and combines with calcium, pushing the calcium-phosphate product toward levels that precipitate in vessel walls. As kidney function declines, phosphate excretion drops, causing hyperphosphatemia. Vascular smooth muscle cells sense high extracellular phosphate and can undergo an osteogenic transformation, producing bone-like matrix and promoting calcium phosphate deposition in the vessels. Calcium-based phosphate binders add extra calcium to the system. That increases both the total calcium load and the calcium-phosphate product, making it easier for calcium phosphate crystals to form in the vasculature. This is why these binders can contribute to vascular calcification, and why non-calcium binders are often favored to limit calcium burden. Options about decreased gut phosphate absorption, elevated calcitonin, or overproduction of vitamin D by immune cells don’t fit this dominant mechanism. Decreased phosphate absorption would not drive the high phosphate levels seen in CKD; calcitonin lowers calcium, not promotes calcification; and vitamin D is not overproduced by immune SAMPLEcells in this context—lunging toward dysregulated vitamin D metabolism in CKD usually involves deficiency or resistance rather than excess production.

Hypercalcemia in granulomatous diseases is driven by macrophage-driven production of active vitamin D outside the kidney, which increases intestinal calcium absorption. Activated macrophages within granulomas express 1α-hydroxylase and convert circulating 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (the active hormone) regardless of PTH levels. This extra calcitriol raises calcium absorption from the gut, pushing serum calcium upward. Because calcium is high, PTH is suppressed, and the hypercalcemia is not due to PTH-driven renal reabsorption or calcitonin changes. Vitamin D status plays a crucial distinction here: deficiency would reduce, not increase, calcium absorption, so it cannot explain hypercalcemia in this context. Treatment focuses on reducing macrophage activity (often with glucocorticoids) and addressing the underlying granulomatous process to limit extrarenal calcitriol production.

Vitamin D deficiency reduces calcium absorption from the gut, leading to low serum calcium. In response, the parathyroid glands secrete more PTH to raise calcium levels, a scenario called secondary hyperparathyroidism. This compensatory rise in PTH increases bone resorption and renal calcium reabsorption (and promotes phosphate wasting), helping to normalize calcium but often keeping phosphate low. So the expected lab finding is an elevated PTH level. A reduced, normal, or absent PTH would not fit the body's compensatory response to hypocalcemia in vitamin D deficiency.